Nektar Therapeutics
NASDAQ:NKTR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.49
1.83
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NKTR stock under the Base Case scenario is 0.6997 USD. Compared to the current market price of 0.9283 USD, Nektar Therapeutics is Overvalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Nektar Therapeutics
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
Valuation History
Historical valuation for NKTR cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Nektar Therapeutics
Balance Sheet Decomposition
Nektar Therapeutics
Current Assets | 286.5m |
Cash & Short-Term Investments | 244.5m |
Other Current Assets | 42m |
Non-Current Assets | 21.5m |
Long-Term Investments | 4.5m |
PP&E | 12.4m |
Other Non-Current Assets | 4.5m |
Current Liabilities | 67.6m |
Accounts Payable | 8.6m |
Accrued Liabilities | 53.9m |
Other Current Liabilities | 5.1m |
Non-Current Liabilities | 191.5m |
Other Non-Current Liabilities | 191.5m |
Earnings Waterfall
Nektar Therapeutics
Revenue
|
93.1m
USD
|
Cost of Revenue
|
-30m
USD
|
Gross Profit
|
63.1m
USD
|
Operating Expenses
|
-199m
USD
|
Operating Income
|
-135.9m
USD
|
Other Expenses
|
-32.4m
USD
|
Net Income
|
-168.3m
USD
|
Free Cash Flow Analysis
Nektar Therapeutics
USD | |
Free Cash Flow | USD |
NKTR Profitability Score
Profitability Due Diligence
Nektar Therapeutics's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Nektar Therapeutics's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
NKTR Solvency Score
Solvency Due Diligence
Nektar Therapeutics's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Nektar Therapeutics's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NKTR Price Targets Summary
Nektar Therapeutics
According to Wall Street analysts, the average 1-year price target for NKTR is 4.794 USD with a low forecast of 1.313 USD and a high forecast of 7.35 USD.
Dividends
Current shareholder yield for NKTR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NKTR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
The intrinsic value of one NKTR stock under the Base Case scenario is 0.6997 USD.
Compared to the current market price of 0.9283 USD, Nektar Therapeutics is Overvalued by 25%.